Although the metabolic syndrome (MetS) is positively associated with high-sensitivity C-reactive protein (hsCRP), negatively associated with N-terminal probrain natriuretic peptide (Nt-proBNP) and inconsequently related to urine albumin/creatinine ratio (UACR) they are all associated with cardiovascular events. Therefore, we wanted to determine the influence of MetS on the predictive values of UACR, hsCRP and Nt-proBNP. On the basis of the definition of MetS by the International Diabetes Federation, a Danish population sample of 1983 apparently healthy subjects was divided into three groups: 530 subjects without any elements of MetS, 1093 subjects with some elements of MetS and 360 subjects with MetS. During the following 9.5 years the composite end point of cardiovascular death, nonfatal myocardial infarction or stroke (composite cardiovascular end point, CEP) occurred in 204 subjects. In Cox-regression analyses adjusting for age, gender and smoking, all three cardiovascular risk markers predicted CEP independently of MetS. Despite no significant interaction with MetS, high log(hsCRP) was associated with CEP primarily in subjects without any elements of MetS (hazard ratio (HR) ¼ 4.5 (1.5-14.0), Po0.01), log(NtproBNP) primarily in subjects with some elements of MetS (HR ¼ 3.0 (1.6-5.6), Po0.01), and logUACR independently of elements of MetS. Pre-specified genderadjusted (men/women) cutoff values of hsCRPX6.0/ 7.3 mg l À1 predicted CEP in subjects without elements of MetS with positive and predictive values of 11.5 and 98%, respectively. UACRX0.73/1.06 mg mmol À1 predicted CEP in subjects with MetS with positive and predictive values of 23.5 and 93%, respectively. In apparently healthy subjects, high hsCRP was associated with CEP primarily in subjects without MetS, high Nt-proBNP in subjects with elements of MetS and UACR independently of MetS.
Introduction
The metabolic syndrome (MetS) is positively associated with high-sensitivity C-reactive protein (hsCRP), 1 negatively associated with N-terminal pro-brain natriuretic peptide (Nt-proBNP) 2 and inconsequently related to urine albumin/creatinine ratio (UACR). 3, 4 High hsCRP, 5, 6 high Nt-proBNP, 7 high UACR 8 and MetS 9, 10 have all been demonstrated to predict cardiovascular (CV) events in the general population. However, the interrelations between these factors are complex. High hsCRP might be associated with MetS, because inflammation may lead to the development of insulin resistance [11] [12] [13] a key factor in MetS. High hsCRP might also be associated with albuminuria 14, 15 which in some studies seems to mediate some of the decremental effects of MetS 3 although other studies have not found any association between MetS and UACR. 4 Furthermore, MetS has been associated with low Nt-proBNP 2 although high Nt-proBNP has been associated with subclinical CV disease. 16, 17 Therefore, the aim of the present study was to investigate whether MetS influenced the ability of hsCRP, Nt-proBNP and UACR to predict the composite CV end point (CEP) of CV death, non-fatal myocardial infarction and non-fatal stroke.
Methods

Study design
In 1982-1984, a random population sample of 4807 individuals aged 31, 41, 51 or 61 years living near Glostrup University Hospital, were invited to participate in a population survey in which 82.6% participated. In 1993-1994, 3785 former participants were re-invited and 2656 (70.2%) accepted and participated in the following investigations. All were followed-up in 2003. In 1993 during a singlestudy visit all traditional CV risk factors were measured and blood samples obtained for analysis of plasma glucose, serum insulin and lipid profile, 18 serum Nt-proBNP and serum hsCRP, and a morning urine sample were collected to calculate UACR. The participants completed a questionnaire concerning their past and current medical history, intake of medication and lifestyle. 17 The study was approved by the local ethical committee and the subjects gave informed consent.
In this study we decided to exclude the subjects receiving medication that could influence any of the CV risk factors and thereby weaken their prognostic value. Therefore, we included the 1983 apparently healthy subjects who did not receive CV medication or had history of diabetes, myocardial infarction or stroke in whom we had available data to determine the presence or absence of MetS defined according to the International Diabetes Federation: 19 Central obesity and two or more elements of MetS. The elements of MetS were central obesity (waist men/women X94/80 cm), elevated serum triglyceride (X1.7 mmol l À1 (150 mg per 100 ml)), reduced serum high-density lipoprotein cholesterol (o1.03/ 1.29 mmol l À1 (40/50 mg per 100 ml) in men/ women), elevated plasma glucose (X5.6 mmol l À1 (100 mg per 100 ml)) or elevated blood pressure (BP, systolic BPX130 mm Hg or diastolic BP X85 mm Hg). The subjects were divided in three groups: 530 subjects without any elements of MetS, 1093 subjects with some elements of MetS without having the syndrome and 360 subjects with MetS. Baseline characteristics are previously described. 17 After 9.5 years, a complete follow-up regarding death was obtained through information from the Civil Registration System until October 2003. Information on CV mortality was obtained from blinded classification of death certificates and information on hospitalisation was recorded from The Danish National Health Register, the data from which have previously been validated. 20 During the follow-up, CEP occurred in 204 subjects (9.4 per 1000 person-years of follow-up) and CV death in 128 subjects (5.8 per 1000 person-years of follow-up).
Blood pressure
Office BP and heart rate were measured sitting after 5 min of rest with the participants arm at heart level with a random zero mercury sphygmomanometer and the mean of two measurements was reported. Heart rate was counted over 15 s.
Assays
Serum hsCRP concentration was determined using a particle-enhanced immunoturbidimetry assay (Roche/Hitachi) range 0.1-20 mg l
À1
and lowest detection limit 0.03 mg l À1 . Serum Nt-proBNP concentration was determined using Elecsys proBNP sandwich immunoassay on an Elecsys 2010 (Roche Diagnostics, Mannheim, Germany). The analytical range was 5.1-34 927 pg ml À1 . Between-assay coefficients of variation in low and high ranges of NtproBNP are reported to be 4.8 and 2.7%. 21 Serum was frozen immediately at À20 1C to be examined in July 2003. We have previously published data showing that hsCRP 1 as well as Nt-proBNP 2 appear to be stable in the frozen samples.
Urine albumin concentration was determined by standard methods 22 using a turbidimetric method (Hitachi 717 Analyzer; Roche Diagnostics) on a single urine specimen taken in the morning. Urine creatinine was analysed using the Jaffé reaction without deproteinizing and then quantified by a photometric method (Hitachi 717 Analyzer; Roche Diagnostics). UACR was calculated.
Statistics
Statistical analyses were performed using SPSS 12.0. (SPSS, Chicago, IL, USA) software. Pearson's w 2 -test was used to determine differences in categorical variables between groups. In Cox-regression analyses we tested for linearity and proportional hazard assumption demonstrating that all three novel risk markers required logarithmic transformation. For log(hsCRP), log(Nt-proBNP) and logUACR, hazard ratios (HRs) and their 95% confidence intervals (in brackets) were assessed in the whole group to test for modulation by MetS group using formal interaction tests. HRs for log(hsCRP), log(NtproBNP) and logUACR were also calculated in each group using univariate as well as multiple Coxregression analyses to adjust for age, gender and smoking habits. Finally, we used SAS software, version 9.1 (SAS Institute, Cary, NC, USA) to calculate the 10-year absolute risk of CV death or CEP at different levels of hsCRP, Nt-proBNP and UACR in each of the three groups.
On the basis of pre-specified gender-adjusted cutoff values with a specificity of 90% in apparently healthy subjects, 23 negative and positive predictive values were calculated for the three novel risk markers in each of the three groups.
Results
With more elements of MetS the prevalence of older men increased (Table 1) . The most prevalent elements of MetS were central obesity and elevated BP ( Table 1 ). The incidence of CEP and CV death increased with more elements of MetS. (Table 2a ) primarily in subjects without any elements of MetS, but the test for interaction between log(hsCRP) and MetS did not reach significance. Despite of the rather high HR, the actual absolute 10-year risk of CV death did not exceed 5% in subjects without any elements of MetS, for any level of hsCRP (data not shown). In unadjusted as well as adjusted models, log(Nt-proBNP) predicted CEP and CV death only in subjects with one or more elements of MetS (Table 2b) , but the test for interaction between log(Nt-proBNP) and MetS did not reach significance. Finally, in unadjusted as well as adjusted Cox-regression models, logUACR predicted CV death and CEP independently of MetS although the prediction of CEP did not reach significance in subjects without any elements of MetS (Table 2c) .
Predictive value of UACR, hsCRP and Nt-proBNP Using pre-specified gender-adjusted cutoff values, negative and positive predictive values were calculated for Nt-proBNP, hsCRP and UACR (Table 3 ). In subjects without any elements of MetS, hsCRP performed the best with a positive and negative predictive value of 11.5 and 98%, respectively. However, in this group, high hsCRP was only found in approximately 5% (26/530) of subjects predicting only three CEPs. In subjects with elements of MetS without having MetS, Nt-proBNP and UACR performed equally well. High Nt-proBNP (128/1070) as well as high UACR (133/1070) was found in 12% of subjects from this intermediate group predicting 19 or 21 CEPs, respectively. In subjects with MetS, UACR performed the best with a high value in 13% 
Discussion
In apparently healthy subjects, all three new risk markers predicted CV events independently of MetS. Despite no significant interaction with MetS, high hsCRP was associated with CEP primarily in subjects without MetS, high Nt-proBNP in subjects with elements of MetS and UACR independently of MetS.
Prognostic performance of hsCRP
In subjects without any elements of MetS, hsCRP predicted CEP as well as CV death probably because hsCRP is a marker of early atherosclerotic changes and closely related to all elements of MetS. This is supported by earlier studies by Ridker et al. 5 in postmenopausal women. HsCRP above the prespecified gender-adjusted cutoff value of 6.0/ 7.3 mg l À1 in men and women, respectively, predicted CEP with a relative high positive predictive value of 11.5%. This represented a fivefold higher event rate compared to the rest of the subjects without any elements of MetS with a very high Abbreviations: ER high , event rate in subjects with high-risk marker; ER low , event rate in subjects with low-risk marker; HsCRP, high-sensitivity C-reactive protein; MetS, the metabolic syndrome; Nt-proBNP, N-terminal pro-brain natriuretic peptide; PV, predictive value; UACR, urine albumin/creatinine ratio. Cutoff values for Nt-proBNP, hsCRP and UACR (men/women) were 110/164 pg ml À1 , 6.0/7.3 mg l À1 and 0.73/1.06 mg mmol À1 . Pearson's w 2 -test: **Po0.01, ***Po0.001.
negative predictive value of 98%. However, high hsCRP was observed only in a few subjects and predicted only three events why the results need to be interpreted with caution. Furthermore, in these subjects without any elements of MetS the actual 10-year risk of CV death did not exceed 5% for any level of hsCRP indicating that even very high levels of hsCRP would not in itself justify primary prevention in these low risk subjects. However, as these subjects were rather young (77% were either 41 or 51 years old) one has to consider relative as well as absolute CV risk to understand the lifetime risk of the subjects.
Prognostic performance of Nt-proBNP High Nt-proBNP predicted CEP as well as CV death in subjects with one or more elements of MetS probably because Nt-proBNP is a marker of subclinical CV hypertrophy and left ventricular dysfunction developing later in the atherosclerotic process. This is supported by several studies in patients with heart failure 24 and acute coronary syndrome 25 as well as by the fact that earlier studies in the general population have demonstrated significant prognostic value of Nt-proBNP in elderly subjects with high probability of subclinical CV disease. 26 This additive prognostic effect of NtproBNP in subjects with elements of MetS is consistent with previous demonstration of a inverse, but relatively weak relationship between Nt-proBNP and traditional metabolic CV risk factors. 2 Prognostic performance of UACR High UACR predicted CEP as well as CV death in all subjects supporting the hypothesis that UACR is a marker of endothelial dysfunction 27 known to precede atherosclerosis 28 as well as a marker of later subclinical microvascular damage. 29 UACR above 0.73/1.06 mg mmol À1 was associated with a threefold higher event rate in all three groups. The negative predictive values were high ranging from 93 to 97% with relatively high positive predictive values making UACR a potentially useful CV risk marker which is supported by previous studies. 30 This additive prognostic effect of UACR independently of MetS reflects the relatively weak association between MetS and UACR. 4 
Clinical implications
On the basis of our data one should consider measuring hsCRP and probably UACR in subjects with history of early CV disease but otherwise low risk of CV disease due to lack of elements of MetS in order to identify candidates for primary prevention. Measuring Nt-proBNP and UACR should be considered in subjects with elements of MetS who are reluctant to comply with primary prevention in order to improve risk stratification further and thereby strengthening the argument for primary prevention in subjects with elevated Nt-proBNP or UACR.
Summary
In apparently healthy subjects, high hsCRP, NtproBNP and UACR predicted CV events independently of MetS. However, high hsCRP was primarily associated with CEP in subjects without MetS, high Nt-proBNP in subjects with one or more elements of MetS and UACR independently of MetS.
Limitations
As the data on prior CV disease were self-reported, we chose a conservative, but probably accurate definition using only prior myocardial infarction or prior stroke as prior CV disease. Although information about medical history was acquired from a questionnaire we are convinced that the subjects in this study did not receive any medication, because the questionnaire was designed to enquire about medication in different ways and we included only subject who actively denied taking any medicine. Although end points were gathered without contacting the subjects we are convinced that CEP is correctly recorded, because The Danish National Health Register is well-validated 20 and CEP is a well-defined CEP.
The fact that 30% of the subjects original examined in 1982-1984 did not participate in 1993-1994, may have reduced the overall CV risk of the population examined in 1993-1994, but due to a complete follow-up in 2003 this may not affect the prognostic effect of the new risk markers. Although, we did not have data on serum creatinine, no subject had severe renal failure and excluding subjects with UACR above 3.5 mg mmol À1 did not change the results significantly (data not shown).
As approximately 5% of subjects had hsCRP410 mg l À1 and 1% had hsCRP425 mg l
À1
and we did not test for infection some of the hsCRP elevation may be due to infection. However, excluding the upper 1 and 5% did not change the results significantly (data not shown) and Ridker and Cook, 31 have previously demonstrated that even very high levels of hsCRP is clinically useful.
What is known about this topic K High-sensitivity C-reactive protein (hsCRP), 5, 6 N-terminal pro-brain natriuretic peptide (Nt-proBNP), 7 urine albumin/ creatinine ratio (UACR) 8 and the metabolic syndrome (MetS) are associated with increased cardiovascular CV risk. 9, 10 K MetS is associated with high hsCRP 1 as well as low Nt-proBNP. 2 What this study adds K In apparently healthy subjects high hsCRP, Nt-proBNP and UACR predicted CV events independently of MetS. K High hsCRP was primarily associated with CEP in subjects without MetS, high Nt-proBNP in subjects with elements of MetS and UACR independently of MetS.
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